Latest news with #RJI
USA Today
12-06-2025
- Sport
- USA Today
Popular and highly ranked Arizona golf course to undergo multi-million dollar renovation
Popular and highly ranked Arizona golf course to undergo multi-million dollar renovation A popular and highly ranked Arizona golf course has closed for the summer for a multi-million dollar renovation. Quintero Golf Club, in the suburb of Peoria northwest of Phoenix, closed June 2 for the four-month project. Quintero is ranked second in Arizona in the recently released Golfweek's Best 2025: Top public-access golf courses in every state, ranked. The course opened in 2000, and this summer's renovation marks the first significant work on the property since it opened. Rees Jones, Quintero's original architect, will oversee the work. Total Turf is the contractor. The renovation calls for a rebuild of all 18 green complexes, work that will include a green resurfacing them with 007XL Bent grass. All tee boxes will be reworked, laser-leveled and resurfaced with 419 Bermuda grass. There are 65 bunkers on the golf course and every one of them will be renovated with new drainage, new bunker linkers and filled with new Augusta white sand. The renovation is expected to be completed by late September. The course will reopen in October after the fall overseed. 'We are so excited to have RJI and Total Turf involved in this project with the primary focus on making Quintero Golf Club even better than before,' said Quintero's GM Mike Poe. The club will also get a renovated practice facility. The practice tee area will be leveled and resurfaced and the practice green will be rebuilt. Quintero, a Troon managed propery, is a par-72 course that tips out at 7,249 yards.
Yahoo
01-04-2025
- Business
- Yahoo
Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order
Auditor Licensing & Personnel Issues Delays Issuance of Audit OpinionThe Company expects to file within 2 weeks TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ('Avicanna' or 'Company') (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, announces that it will miss the deadline of March 31, 2025 ('Filing Deadline') to file the Company's audited consolidated financial statements for the year ended December 31, 2024 as required by National Instrument 51-102 and the Company's Management's Discussion & Analysis for the year ended December 31, 2024 (the 'Documents'). The Company's auditor, Ramirez Jimenez International CPAs ('RJI') informed the Company that although the audit work is substantially complete and they are prepared to issue the audit opinion, they are not able to do so prior to the filing deadline of March 31, 2025, due to unexpected matters. RJI has substantially finalized the 2024-year end audit engagement and has obtained a third-party engagement quality review (an EQR); however, due to the internal-RJI personnel and jurisdictional licensing issue that recently arose, RJI will not be able to issue the audit report by the filing deadline. RJI is addressing the matter and anticipates that it will not take more than two weeks to resolve the matter and issue the audit opinion, at which time the Company will also file the MD&A and Annual Information Form. Accordingly, the Company has informed staff of the Ontario Securities Commission about its anticipated delay in filing the Documents and has applied to the Ontario Securities Commission pursuant to Part 4 of National Policy 12-203 – Management Cease Trade Orders ('NP 12-203') for a Management Cease Trade Order ('MCTO') pending the filing of the Documents, which MCTO will prohibit the Company's management from trading in the securities of the Company until such time as the Documents are filed. No decision has yet been made by the Ontario Securities Commission on this application. The Ontario Securities Commission may grant the application and issue the Management Cease Trade Order, or it may impose an issuer cease trade order. There can be no assurance that a MCTO will be issued. The Company will comply with the alternative information guidelines set out in Section 9 of NP 12-203 and will file bi-weekly default status reports in the form of press releases. The Company anticipates and expects to file the Documents by April 15, 2025. The Company also announces the 2024 Full Year Earnings Conference Call scheduled for April 1, 2025, which was previously announced on March 18, 2025, will be postponed to a later date. About Avicanna: Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars. Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets. Medical cannabis care platform ( is a medical cannabis care platform formed with the aim to better serve medical cannabis patients' needs and enhance the medical cannabis patients' journey. is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens. Pharmaceutical pipeline: Leveraging Avicanna's scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders. Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company's majority owned subsidiary Santa Marta Golden Hemp SAS ('SMGH') is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company's international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company's supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally. SOURCE Avicanna Inc. Stay Connected For more information about Avicanna, visit our website or contact Ivana Maric by email at info@ Cautionary Note Regarding Forward-Looking Information and Statements This news release contains 'forward-looking information' within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, 'may', 'would', 'could', 'will', 'likely', 'expect', 'anticipate', 'believe', 'intend', 'plan', 'forecast', 'project', 'estimate', 'outlook' and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Offering, the use of proceeds of the Offering, the receipt of all approvals of the Toronto Stock Exchange in connection with the Offering, statements with respect to the Company's future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company's annual information form dated April 1, 2024, filed with the Canadian securities regulators and available under the Company's profile on SEDAR+ at The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
